Birth Control

PCOS renamed polyendocrine metabolic ovarian syndrome, updated ACOG cervical cancer screening guidelines, doxy-PEP losing effectiveness against gonorrhea

Stroke risk with CHC and triptan co-use, IUD self-removal patient perspectives and simulation, LMP dating accuracy in adolescents, intravaginal vitamin C for recurrent BV, sexual health concerns and contraceptive discontinuation, letrozole-misoprostol as mifepristone alternative, OB-GYN job satisfaction post-Dobbs

COCs vs POPs for heavy menstrual bleeding, five-year Miudella copper IUD data, VTE risk with body-identical estrogen COCs, OTC Opill self-screening, mood symptoms and progestin-only discontinuation, Dobbs and residency application trends

How to prevent fainting in your patients, your friends, your family, and yourself in one simple step.

Probiotics as adjunct therapy for recurrent VVC, structured ACOG guidance on unexplained elevated hCG, paracervical block efficacy for IUD pain, menstrual blood HPV testing accuracy, telemedicine medication abortion outcomes

Evidence increasingly shows that person-centered contraceptive counseling is essential to delivering high-quality, equitable contraceptive care.

A 24-year-old patient (she/her) comes in after missing a period. She has a history of PCOS and irregular periods, but reports her periods have been fairly regular over the past several months. In the clinic, her urine pregnancy test is positive. She is surprised and upset, as she’s been using a combined oral contraceptive (COC) for the past 2 years. On further history, you learn she started a weekly GLP-1 injectable for weight loss about 6 months ago that she gets from a local med spa. She doesn’t remember the exact name but thinks it starts with a “s.” Since starting the injection, she’s had intermittent nausea and a few episodes of vomiting, especially in the days after injections and after she increases the dose. She asks “how did this happen?”

Patient interest in self-collected HPV screening, one-dose HPV vaccine effectiveness, adolescents’ lower rates of person-centered contraceptive counseling, LNG-IUD dose and acne risk, FDA approval of new oral gonorrhea therapies